ResMed Inc. vs STRYKER CORP, two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Neither growth rate is on this page, but the multiples assign them: Stryker at 38.5 times earnings is priced to keep compounding, ResMed at 19.3 to merely persist. The income statements read the other way, ResMed's 34.9% operating margin more than doubling Stryker's 15.6%, its 27.4% net against 13.2%, its 17.3% return on assets against 7.2%. ResMed also yields more cash, 6% against 3.6%, with the bigger dividend. Stryker's premium is earned reputation, an acquisition engine that has never missed for long; ResMed's discount is one anxiety, GLP-1 drugs thinning the apnea pipeline, applied against evidence that has yet to arrive. Nineteen turns for a fear versus a track record: the sector's clearest sentiment spread.
Comparison updated 2026-07-10.
| Metric | RMD | SYK |
|---|---|---|
| Price | $200.28 | $332.30 |
| Market cap | $29.2B | $128.4B |
| Sector | Medical Devices | Medical Devices |
| Stage | Mature | Mature |
| Implied growth (priced in) | +4.3% | +23.7% |
| P/E | 19.3 | 38.5 |
| P/B | 4.50 | 5.59 |
| P/S | 5.27 | 5.08 |
| EV/EBITDA | 13.3 | 21.3 |
| Revenue growth | +10.3% | +8.8% |
| Gross margin | 62.3% | 63.3% |
| Operating margin | 34.9% | 15.6% |
| Net margin | 27.4% | 13.2% |
| Return on equity | 23.4% | 14.5% |
| Return on assets | 17.3% | 7.2% |
| Return on invested capital | 21.0% | 11.6% |
| FCF yield | 6.0% | 3.6% |
| Dividend yield | 1.1% | 0.5% |
| Debt / equity | 0.10 | 0.64 |
| Current ratio | 3.01 | 2.11 |
| Altman Z (solvency) | 8.30 | 4.73 |
| Piotroski F (quality) | 7 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.